Home

Merck & Co (MRK)

82.63
-1.43 (-1.70%)
NYSE · Last Trade: Jul 29th, 4:55 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close84.06
Open79.85
Bid82.56
Ask82.60
Day's Range76.66 - 82.89
52 Week Range73.31 - 127.99
Volume27,250,687
Market Cap209.17B
PE Ratio (TTM)12.03
EPS (TTM)6.9
Dividend & Yield3.240 (3.92%)
1 Month Average Volume12,457,024

Chart

About Merck & Co (MRK)

Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More

News & Press Releases

Why Merck (MRK) Shares Are Sliding Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a new multi-year cost-cutting initiative. The pharmaceutical giant posted total sales of $15.8 billion, representing a 2% decrease from the same period last year. This revenue shortfall was primarily driven by a steep 55% drop in sales for its Gardasil vaccine, which faced declining demand in China. While the company's earnings per share beat analysts' forecasts, investors appeared to focus on the top-line miss. Alongside the earnings, Merck announced a major restructuring plan aimed at saving $3 billion annually through measures that included layoffs and real estate reductions. The company stated these savings would be reinvested to support new product launches and its research pipeline.
Via StockStory · July 29, 2025
Is Merck & Co Gaining or Losing Market Support?benzinga.com
Via Benzinga · July 29, 2025
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challengesbenzinga.com
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.
Via Benzinga · July 29, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends.
Via Chartmill · July 29, 2025
Earnings Scheduled For July 29, 2025benzinga.com
Via Benzinga · July 29, 2025
Merck & Co's Earnings Outlookbenzinga.com
Via Benzinga · July 28, 2025
P/E Ratio Insights for Merck & Cobenzinga.com
Via Benzinga · July 24, 2025
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?benzinga.com
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
Via Benzinga · July 29, 2025
Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Planstocktwits.com
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said.
Via Stocktwits · July 29, 2025
Merck Posts Q2 EPS Beat Revenue Slipsfool.com
Via The Motley Fool · July 29, 2025
Which S&P500 stocks are moving before the opening bell on Tuesday?chartmill.com
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · July 29, 2025
Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64.8 billion at the midpoint. Its non-GAAP profit of $2.13 per share was 5% above analysts’ consensus estimates.
Via StockStory · July 29, 2025
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025.
By Merck & Co., Inc. · Via Business Wire · July 29, 2025
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Foreverfool.com
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pactbenzinga.com
GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
Via Benzinga · July 28, 2025
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earningsbenzinga.com
Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.
Via Benzinga · July 28, 2025
3 Surprisingly Underrated Stocks to Buy Right Nowfool.com
These big pharma stocks arguably aren't receiving the respect they deserve.
Via The Motley Fool · July 28, 2025
What To Expect From Merck’s (MRK) Q2 Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.
Via StockStory · July 27, 2025
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pillsbenzinga.com
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via Benzinga · July 26, 2025
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharmabenzinga.com
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.
Via Benzinga · July 25, 2025
Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potentialchartmill.com
Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.
Via Chartmill · July 25, 2025
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Resultsinvestors.com
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stockinvestors.com
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.
Via Investor's Business Daily · July 22, 2025
Merck Announces Fourth-Quarter 2025 Dividend
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025.
By Merck & Co., Inc. · Via Business Wire · July 22, 2025
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentalschartmill.com
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.
Via Chartmill · July 22, 2025